scholarly journals A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Blood ◽  
2015 ◽  
Vol 125 (26) ◽  
pp. 4024-4031 ◽  
Author(s):  
Achim Rothe ◽  
Stephanie Sasse ◽  
Max S. Topp ◽  
Dennis A. Eichenauer ◽  
Horst Hummel ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Brentuximab Vedotin ◽  
Phase 1 Study ◽  
Killer Cells ◽  
New Approach ◽  
Key Points ◽  
Refractory Hodgkin Lymphoma

Key Points The bispecific, tetravalent antibody AFM13 represents a new approach engaging natural killer cells via CD16A to fight CD30+ malignancies. AFM13 is well tolerated and active in Hodgkin lymphoma patients who received all standard therapies, including brentuximab vedotin.

scholarly journals Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Blood ◽  
2014 ◽  
Vol 123 (5) ◽  
pp. 678-686 ◽  
Author(s):  
Holbrook E. Kohrt ◽  
Ariane Thielens ◽  
Aurelien Marabelle ◽  
Idit Sagiv-Barfi ◽  
Caroline Sola ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
Mhc Class I ◽  
Nk Cell ◽  
Class I ◽  
Lymphoma Cells ◽  
Killer Cells ◽  
Key Points ◽  
Anti Cd20 ◽  
Cd20 Antibodies

Key Points Blockade of inhibitory KIRs with MHC class I antigens on lymphoma cells by anti-KIR antibodies augments NK-cell spontaneous cytotoxicity. In combination with anti-CD20 mAbs, anti-KIR induces enhanced NK cell–mediated, rituximab-dependent cytotoxicity against lymphoma.

scholarly journals Classification of human natural killer cells based on migration behavior and cytotoxic response

Blood ◽  
2013 ◽  
Vol 121 (8) ◽  
pp. 1326-1334 ◽  
Author(s):  
Bruno Vanherberghen ◽  
Per E. Olofsson ◽  
Elin Forslund ◽  
Michal Sternberg-Simon ◽  
Mohammad Ali Khorshidi ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Nk Cells ◽  
Natural Killer ◽  
Serial Killer ◽  
Migration Behavior ◽  
Killer Cells ◽  
Key Points ◽  
Human Natural Killer Cells ◽  
Cytotoxic Responses

Key Points Activated NK cells display heterogeneity in their cytotoxic responses that justifies grouping them into 5 distinct classes of NK cells. A subpopulation of particularly active “serial killer” NK cells deliver their lytic hits faster and release more perforin in each hit.

scholarly journals A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia

2018 ◽  
Vol 24 (8) ◽  
pp. 1581-1589 ◽  
Author(s):  
Todd A. Fehniger ◽  
Jeffrey S. Miller ◽  
Robert K. Stuart ◽  
Sarah Cooley ◽  
Amandeep Salhotra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Myeloid Leukemia ◽  
Phase 1 ◽  
Killer Cells ◽  
Phase 1 Trial ◽  
Acute Myeloid

scholarly journals Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response

2016 ◽  
Vol 1 (3) ◽  
pp. 208-218 ◽  
Author(s):  
Rachel J. Bergerson ◽  
Robin Williams ◽  
Hongbo Wang ◽  
Ryan Shanley ◽  
Gretchen Colbenson ◽  
...  
Keyword(s):  
Natural Killer Cells ◽  
Cord Blood ◽  
Nk Cells ◽  
Natural Killer ◽  
Nk Cell ◽  
Cord Blood Transplantation ◽  
Killer Cells ◽  
Cell Numbers ◽  
Blood Transplantation ◽  
Key Points

Key Points Low numbers of reconstituting NK cells at D+28 after dUCBT are associated with inferior DFS. Patients with low NK cell numbers at D+28 have reduced phosphorylation of STAT5 upon IL-15 stimulation and less Eomes expression.

scholarly journals Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3

Blood ◽  
2015 ◽  
Vol 125 (4) ◽  
pp. 639-648 ◽  
Author(s):  
Emma M. Haapaniemi ◽  
Meri Kaustio ◽  
Hanna L. M. Rajala ◽  
Arjan J. van Adrichem ◽  
Leena Kainulainen ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
T Cell ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Mycobacterial Disease ◽  
Killer Cells ◽  
Activating Mutations ◽  
Key Points ◽  
Stat3 Mutations

Key Points Germline activating STAT3 mutations were detected in 3 patients with autoimmunity, hypogammaglobulinemia, and mycobacterial disease. T-cell lymphoproliferation, deficiency of regulatory and helper 17 T cells, natural killer cells, dendritic cells, and eosinophils were common.

scholarly journals INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

2017 ◽  
Vol 35 ◽  
pp. 85-86 ◽  
Author(s):  
A.F. Herrera ◽  
A.J. Moskowitz ◽  
N.L. Bartlett ◽  
J.M. Vose ◽  
R. Ramchandren ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Brentuximab Vedotin ◽  
Refractory Hodgkin Lymphoma
Sign in / Sign up

Export Citation Format

Share Document